Association of Serum hs‐ CRP and TNF ‐α With Therapeutic Response to Erenumab for Migraine Prevention: A Registry for Migraine ( REFORM ) Study
European Journal of Neurology · 2026-07 · 33 (7)
DOI: 10.1111/ene.70714 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift European Journal of Neurology, online erschienen am 24.07.2026. Verfasst von William K Karlsson und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Center for Discoveries in Migraine and Danish Headache Center, Copenhagen University Hospital - Rigshospitalet, Copenhagen, …. Hauptthemen laut MEDLINE: Migraine Disorders, Tumor Necrosis Factor-alpha, C-Reactive Protein, Antibodies, Monoclonal, Humanized. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Lundbeck Foundation, Danmarks Grundforskningsfond.
Abstract (Originalsprache)
Background
Experimental studies show inflammatory cytokines can modulate calcitonin gene‐related peptide (CGRP) signaling, suggesting systemic inflammatory markers might reflect biological processes relevant to anti‐CGRP therapies. We aimed to determine whether serum high‐sensitivity C‐reactive protein (hs‐CRP) and tumor necrosis factor‐alpha (TNF‐α) are associated with erenumab response in adults with migraine and assess longitudinal biomarker changes during and after treatment.
Methods
In this prospective, observational single‐center study, adults with episodic or chronic migraine self‐administered 140 mg erenumab subcutaneously every 4 weeks for 24 weeks. Serum was collected at baseline, Week 24 (end of treatment), and Week 48 (24 weeks post‐treatment). Treatment response was defined as a ≥ 50% reduction in monthly migraine days from baseline to Weeks 13–24. Logistic and linear regression models evaluated associations between baseline biomarkers and response, while longitudinal changes were analyzed using linear mixed‐effects models.
Results
Of 679 enrolled participants, serum was analyzed in 623. Among 541 with sufficient data to determine response, 281 (51.9%) were responders. Neither baseline hs‐CRP (OR 1.04; 95% CI 0.96–1.12; p = 0.30) nor TNF‐α (OR 0.75; 95% CI 0.49–1.16; p = 0.20) predicted treatment response. TNF‐α increased from baseline to Week 24 (mean rise 3.0%; 95% CI 0.5%–5.4%; p = 0.030), but no responder–non‐responder differences were found.
Conclusions
Peripheral inflammatory biomarkers such as hs‐CRP and TNF‐α neither predict response nor change meaningfully during CGRP‐receptor blockade. These results suggest broadly applied inflammatory markers do not capture treatment‐relevant biology and highlight the need for mechanism‐specific biomarkers to advance personalized migraine therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Center for Discoveries in Migraine and Danish Headache Center, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.
- Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
- Translational Research Center, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.
- Department of Regional Health Research, University of Southern Denmark, Odense, Denmark.
- Department of Biochemistry and Immunology, University Hospital of Southern Denmark - Lillebaelt Hospital, Vejle, Denmark.
- Department of Health Technology, Technical University of Denmark, Kongens Lyngby, Denmark.
ORCID-Profile: William K Karlsson, Rune H Christensen, Haidar M Al-Khazali, Dorte A Olsen, Jonna S Madsen, Messoud Ashina, Håkan Ashina
Förderung
- Lundbeck Foundation
- Danmarks Grundforskningsfond
Zitieren
APA
Karlsson, W. K., Christensen, R. H., Al-Khazali, H. M., Olsen, D. A., Madsen, J. S., Ashina, M., & Ashina, H. (2026). Association of Serum hs‐ CRP and TNF ‐α With Therapeutic Response to Erenumab for Migraine Prevention: A Registry for Migraine ( REFORM ) Study. European Journal of Neurology, 33(7). https://doi.org/10.1111/ene.70714
Vancouver
Karlsson WK, Christensen RH, Al-Khazali HM, Olsen DA, Madsen JS, Ashina M, et al. Association of Serum hs‐ CRP and TNF ‐α With Therapeutic Response to Erenumab for Migraine Prevention: A Registry for Migraine ( REFORM ) Study. European Journal of Neurology. 2026;33(7). doi:10.1111/ene.70714
BibTeX
@article{Karlsson2026,
author = {Karlsson, William K and Christensen, Rune H and Al-Khazali, Haidar M and Olsen, Dorte A and Madsen, Jonna S and Ashina, Messoud and Ashina, Håkan},
title = {Association of Serum hs‐ CRP and TNF ‐α With Therapeutic Response to Erenumab for Migraine Prevention: A Registry for Migraine ( REFORM ) Study},
journal = {European Journal of Neurology},
year = {2026},
volume = {33},
number = {7},
doi = {10.1111/ene.70714}
}
EUVIMED